Sign In
Buy AKYA
$1.29
+0 (+0%)
At Close: Oct 07, 2025
NEW ORLEANS , June 20, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
02:21pm, Friday, 23'rd May 2025
RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company"
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates
06:30pm, Monday, 12'th May 2025
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.
Akoya Biosciences Reports First Quarter 2025 Financial Results
04:05pm, Monday, 12'th May 2025
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter en
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosci
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:05am, Monday, 05'th May 2025
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
07:00am, Tuesday, 29'th Apr 2025
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
08:00am, Thursday, 24'th Apr 2025
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient,
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
08:00am, Thursday, 24'th Apr 2025
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibo
The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world s
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences
08:00am, Monday, 14'th Apr 2025
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“
